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Abstract
Background and Objectives The kidney is a major drug-
eliminating organ. Renal impairment or concomitant use of
transporter inhibitors may decrease active secretion and
increase exposure to a drug that is a substrate of kidney
secretory transporters. However, prediction of the effects of
patient factors on kidney transporters remains challenging
because of the multiplicity of transporters and the lack of
understanding of their abundance and specificity. The
objective of this study was to use physiologically based
pharmacokinetic (PBPK) modelling to evaluate the effects
of patient factors on kidney transporters.
Methods Models for three renally cleared drugs (osel-
tamivir carboxylate, cidofovir and cefuroxime) were
developed using a general PBPK platform, with the con-
tributions of net basolateral uptake transport (Tup,b) and
apical efflux transport (Teff,a) being specifically defined.
Results and Conclusion We demonstrated the practical
use of PBPK models to: (1) define transporter-mediated
renal secretion, using plasma and urine data; (2) inform a
change in the system-dependent parameter (C10-fold
reduction in the functional ‘proximal tubule cells per gram
kidney’) in severe renal impairment that is responsible for
the decreased secretory transport activities of test drugs; (3)
derive an in vivo, plasma unbound inhibition constant of
Tup,b by probenecid (B1 lM), based on observed drug
interaction data; and (4) suggest a plausible mechanism of
probenecid preferentially inhibiting Tup,b in order to alle-
viate cidofovir-induced nephrotoxicity.
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AUC Area under the concentration–time curve
B/P Blood to plasma partition ratio
CLCR Creatinine clearance
CLint,T Transporter-mediated intrinsic clearance
CLiv In vivo clearance
CLpd Passive diffusion clearance
CLr Renal clearance
CLr,T Renal clearance mediated by a transporter
DDI Drug–drug interaction
fa Fraction available from dosage form
fu,p Fraction unbound in plasma
GFR Glomerular filtration rate
[I] Plasma unbound inhibitor concentration
ka First-order absorption rate constant
Ki Reversible inhibition constant
Kp Tissue-to-plasma partition coefficient
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Teff,a Efflux transporter on apical membrane
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1 Introduction
Despite their often secondary role, compared with the
liver’s capacity to eliminate drugs, the kidneys should not
be overlooked. In fact, approximately 30 % of approved
drugs show renal clearance as their main route of elimi-
nation [1, 2].
Renal clearance is a net result of glomerular filtration,
reabsorption and secretion. Secretion is the transport of
substances from the renal blood to the lumen of the
nephron. It occurs predominantly in the proximal tubules,
via transporters on the basolateral and apical membranes to
facilitate the uptake and efflux, respectively, of substances
into urine. Using a generic physiologically based pharma-
cokinetic (PBPK) model structure (Fig. 1), one can visu-
alize the contributions of both passive and active processes
in drug movement across the basolateral membrane
(between blood and cells) and apical membrane (between
cells and urine) of a proximal tubule epithelial cell to drug
distribution and elimination in the kidneys.
Renal clearance of drugs may be significantly affected
by intrinsic and extrinsic patient factors, such as renal
impairment and/or drug–drug interactions (DDIs). When
active secretion represents a major contributor to a drug’s
total clearance, the effects of these patient factors on renal
transporter function and overall renal clearance can cause
significant changes in the disposition of the affected drug.
The objective of this study was to explore the utility of
PBPK modelling to evaluate the effects of renal impair-
ment and transporter-interacting drugs on drug exposure
and safety. Specifically, we aimed to (1) demonstrate the
use of PBPK to model renal active secretion by trans-
porters; (2) explore how a system-dependent parameter
may be associated with renal impairment; (3) evaluate the
utility of PBPK to predict the effect of competitive trans-
porter inhibition via the interacting drug probenecid on the
pharmacokinetics of three renally eliminated drugs; and (4)
identify the roles of renal transporters and inhibitors in
nephrotoxicity associated with renally cleared drugs.
2 Methods
2.1 Model Drugs
PBPK models of oseltamivir carboxylate, cidofovir and
cefuroxime were built using the population-based PBPK
software Simcyp Simulator (version 12.1; Simcyp Ltd,
Sheffield, UK). All three drugs are predominantly renally
cleared (cidofovir *90 %) or exclusively renally cleared
(oseltamivir carboxylate and cefuroxime *100 %) (see
Table 1).
Drug-dependent parameters for oseltamivir carboxylate,
cidofovir and cefuroxime PBPK models were derived from
a variety of sources (Table 1). In addition to in vitro and
in vivo data, in silico predictions of certain physicochem-
ical properties, including the partition coefficient (LogP),
compound type, dissociation constant (pKa) and blood to
plasma partition ratio (B/P), were made using data from the
following publicly available sources: ChemSpider, the free
chemical database (http://www.chemspider.com; Royal
Society of Chemistry, Cambridge, UK), ADMET Predic-
torTM version 6 (Simulations Plus, Inc., Lancaster, CA,
USA) and PubChem (http://pubchem.ncbi.nlm.nih.gov;
National Institutes of Health, Bethesda, MD, USA). Dis-
tribution parameters, including the volume of distribution
at steady state (Vss) and tissue-to-plasma partition coeffi-
cient (Kp), were predicted [3, 4] and, if necessary, opti-
mized using the Kp scalar function based on cited in vivo
human data. Cidofovir and cefuroxime were both dosed
intravenously, whereas oseltamivir carboxylate, the active
metabolite, was formed from orally administered osel-
tamivir phosphate. To approximate the rate and extent of
the appearance of oseltamivir carboxylate in plasma, oral
parameters fa (fraction absorbed) and ka (first-order
absorption rate constant) were used to represent the rate
and extent of conversion from the parent drug to osel-
tamivir carboxylate. Detailed PBPK model development
for each substrate can be found in the Electronic Supple-
mentary Material, including the use of various techniques
(e.g. retrograde calculation, parameter estimation and
sensitivity analysis methods of the software). When nee-
ded, mean plasma or serum concentration–time data points
from cited observed studies were digitized using GetData
Graph Digitizer software (http://getdata-graph-digitizer.
com).
The system-dependent parameters used in our models
were based on existing population data [5] in Simcyp.
The mechanistic kidney model within the simulator was
used to capture the differential processes relating to renal
clearance [1]. Briefly, the model described the necessary
processes governing drug transfer from blood to the urine
through kidney cells, including passive diffusion, basolat-
eral transporters (i.e. blood $ cell), apical transporters (i.e.
284 V. Hsu et al.
cell $ tubule) and the glomerular filtration rate (GFR).
A Cockcroft–Gault equation based on predefined creatinine
clearances in the existing Simcyp population data was used
to calculate the GFR. This mechanistic kidney model was
then connected to the whole-body PBPK model structure
through blood flow terms as illustrated in Fig. 1. The major
assumptions made for this work are discussed below.
2.1.1 Negligible Passive Diffusion for Highly Hydrophilic
Drugs
Since model substrate drugs are all hydrophilic and are
generally ionized at physiological pH, the basolateral
passive diffusion clearance (i.e. blood $ cell) and the
apical passive diffusion clearance (i.e. cell $ tubule) were
deemed negligible and were thus assumed to be zero.
Accordingly, passive reabsorption was also assumed to be
negligible.
2.1.2 Use of ‘Global’ Basolateral Uptake and Apical
Efflux Transporters
In the absence of convincing transporter specificity data to
properly define secretion of these drugs, a ‘global’ basolat-
eral uptake transporter and a ‘global’ apical efflux trans-
porter were assumed to be responsible for drug transport.
This allowed the model to cover the ‘net’ transporter-medi-
ated clearances on both membranes (Fig. 1). Technically, a
basolateral transporter in the software was assumed to cap-
ture net uptake (Tup,b, uptake transporter on basolateral
Fig. 1 Passive and active processes of drug movement across the
basolateral and apical membranes of kidney proximal tubule cells.
a For all drug models in this study, a full physiologically based
pharmacokinetic (PBPK) model in Simcyp Simulator was used. The
kidney compartment used a ‘mechanistic kidney module’ with major
transporters [1], which has been simplified in the figure with urine,
tubule cell and blood compartments to illustrate the three major renal
clearance processes: passive diffusion clearance (CLpd, on both
membranes), net uptake of the drug into tubule cells from the blood
(intrinsic transporter clearance, CLint,T), and net efflux of drug into
the urine from the cells (efflux intrinsic transporter clearance,
CLint,efflux).
b Net basolateral uptake and apical efflux are represented
by ‘lumped’ transporter processes Tup,b and Teff,a; each is composed of
different transporters that move drugs in different directions at each
side of the tubular cell. ADME absorption, distribution, metabolism,
and excretion, B/P blood to plasma partition ratio, CLint,T,eff efflux
transporter-mediated intrinsic clearance, CLint,T,up uptake transporter-
mediated intrinsic clearance, CLiv in vivo clearance, CLr renal
clearance, CLr,T renal clearance mediated by a transporter, fa fraction
available from dosage form, fu,p fraction unbound in plasma, ka first-
order absorption rate constant, LogP partition coefficient, MW
molecular weight, Peff,man effective permeability, pKa dissociation
constant, Vss volume of distribution at steady state
PBPK Modelling of Renally Cleared Drugs 285
membrane), and an apical transporter was assumed to cap-
ture net efflux (Teff,a, efflux transporter on apical membrane).
2.1.3 Same Transporter Activity for Each Functional
Proximal Tubular Cell in Patients with Severe Renal
Impairment
The effect of severe renal impairment on renal transporters
was modelled by decreasing the absolute number of func-
tional tubular cells via the system-dependent parameter
PTCPGK (proximal tubular cells per gram kidney). This
parameter extrapolates transporter activity at the cellular
level to that of the whole organ (see Sect. 2.3).
The transporter-mediated intrinsic clearance (CLint,T)
for Tup,b was determined via parameter estimation against
plasma/serum drug concentration–time profile data
observed clinically, using the software’s ‘Healthy Volun-
teers’ population. Once this parameter was established, the
CLint,T for Teff,a was optimized using sensitivity analysis to
match the simulated drug accumulation in the urine to that
observed in the same published study. A higher-fold CLint,T
was then assumed to assure appropriate efflux of the drug
into urine (see sections 1.1–1.3 in the Electronic Supple-
mentary Material). It has to be noted that the CLint,T for
Teff,a was generally unidentifiable with the available data
for each substrate.
Table 1 Drug-dependent parameter summary table for oseltamivir carboxylate, cidofovir and cefuroxime
Parameter Oseltamivir carboxylate Cidofovir Cefuroxime
Renal clearance by active
secretion (%)
62 39 55
Molecular weight (g/mol) 312.4a 279.2a 424.4a
LogP -2.1b -1.5a -0.9a
Compound type Ampholyteb Monoprotic acidc Monoprotic acida
Acid pKa 3.6b 6.9c 3.15a
Base pKa 8.2b N/A N/A
B/P 0.60b 0.98c 0.56c
fu,p 0.97
b 0.90 (0.56 in severe RI)d 0.67e
Vss (L/kg) 0.44
f 0.49f 0.20f
Kp scalar 1.0 1.5 (optimized based on serum
concentration–time IV profile)g








N/A 0.41 (retrograde analysis; sensitivity





12.0 (optimized based on plasma
concentration–time profile)g
3.33 (optimized based on serum
concentration–time profile)g





1 ([0.001 based on urine data)g 20 ([0.2 based on urine data)g 10 ([0.1 based on urine data)g
fa 0.80
h N/A N/A
ka (1/h) 0.15 (optimized)
g N/A N/A
Lag time (h) 0.60 (optimized)g N/A N/A
B/P blood to plasma partition ratio, CLint,T in vitro transporter-mediated intrinsic clearance, CLiv in vivo clearance, CLr renal clearance, fa
fraction available from dosage form, fu,p fraction unbound in plasma, IV intravenous, ka first-order absorption rate constant, Kp tissue-to-plasma
partition coefficient, LogP partition coefficient, N/A not applicable, pKa dissociation constant, RI renal impairment, Teff,a efflux transporter on
apical membrane, Tup,b uptake transporter on basolateral membrane, Vss volume of distribution at steady state
a From ChemSpider (http://www.chemspider.com; Royal Society of Chemistry, Cambridge, UK)
b From Parrott et al. [27]
c From ADMET PredictorTM (Simulation Plus, Lancaster, CA, USA)
d From Cundy [9]
e From Foord [28]
f Predicted from Rodgers et al. (known as Method 2 in Simcyp) [3, 4]
g Optimization involves manual or automated sensitivity analysis, or parameter estimation techniques
h Based on an absolute bioavailability study of the parent compound oseltamivir phosphate [29]
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2.2 The Inhibitor Drug
Probenecid was selected as the perpetrator drug to inhibit
Tup,b defined in the PBPK models of each drug, because
Tup,b is the rate-determining process affecting systemic
exposure to these drugs. In addition, probenecid appears to
be a much stronger inhibitor of basolateral uptake trans-
porters (University of Washington Metabolism and
Transporter database: http://www.druginteractioninfo.org).
Inhibition of Teff,a by probenecid was explored in simula-
tion of cidofovir-induced nephrotoxicity (Sect. 2.5 below).
Section 2 in the Electronic Supplementary Material sum-
marizes the model development for probenecid.
2.3 Simulation of Renal Impairment
The software’s pre-existing populations of ‘Renal-
GFR_less_30’ and ‘Healthy Volunteers’, which included
known physiological differences between healthy and renal
impairment populations [6], were used for the severe renal
impairment and healthy virtual subject simulations,
respectively. Within the software’s PBPK framework,
kidney transporter activity, or drug intrinsic clearance at
the level of the transporter protein, is scaled to whole organ
clearance according to Eq. 1 [1].
CLr;T ¼ CLint;T  PTCPGK  ðkidney weightÞ ð1Þ
where CLr,T is renal clearance mediated by a transporter
with a unit of litres per hour, CLint,T is intrinsic clearance
of Tup,b or Teff,a with a unit of microlitres per minute per
million tubule cells, PTCPGK has a unit of million prox-
imal tubular cells per gram kidney (default healthy = 60
million PTCPGK) and kidney weight has a unit of grams.
Kidney CLint,T for Tup,b or Teff,a is therefore parameterized
with system-dependent parameters (i.e. PTCPGK and
kidney weight) and a drug-dependent parameter (i.e.
intrinsic clearance) at the level of the transporter protein
(Eq. 1).
The default value of PTCPGK in ‘RenalGFR_less_30’ is
the same as that in ‘Healthy Volunteers’ (60 million
PTCPGK). In order to assess the effect of severe renal
impairment on transporter activities, a sensitivity analysis
of a range of PTCPGK values (0.1–60 million; kidney
weight was assumed to be unchanged) was conducted to
compare the predicted area under the concentration–time
curve ratio (AUCR) between subjects with severe renal
impairment (RI) and those with normal renal function
(AUCRRI/Normal) and the AUCR values observed in renal
impairment studies involving each of the three drugs.
While the values of the unbound plasma fraction (fu,p) of
oseltamivir carboxylate and cefuroxime remained
unchanged in the renal impairment population [7, 8], the
fu,p of cidofovir was decreased from 0.90 in the healthy
population to 0.56 in the renal impairment population [9].
The fu,p = 0.56 was then used in the renal impairment
simulations for cidofovir.
2.4 Simulation of Renal Drug–Drug Interaction
The effect of co-administration of oral probenecid on each
substrate drug was simulated. Probenecid was assumed to
only inhibit Tup,b. The inhibition mechanism assumed
reversible inhibition according to Eq. 2:
CLint;Tðwithout inhibitorÞ
CLint;Tðwith inhibitorÞ
¼ 1 þ ½I
Ki
ð2Þ
where [I] is the plasma unbound inhibitor concentration
and Ki is the plasma unbound reversible inhibition constant
[1].
Considering the reported in vitro IC50 and Ki values of
probenecid, which ranged from 1 to 30 lM, with different
organic anion transporter (OAT) substrates [10–12], a
sensitivity analysis using a range of Ki values
(0.1–100 lM) was performed to compare the predicted
AUCR (with and without an inhibitor, AUCR?inhibi-
tor/-inhibitor) with AUCR values observed in DDI studies
involving probenecid and each of the three drugs. The
software’s ‘Healthy Volunteers’ population was used in
these simulations.
2.5 Simulation of Potential Nephrotoxicity
Cidofovir has known nephrotoxic effects and is prescribed
with probenecid as a preventive measure [13, 14]. To
assess the amount of cidofovir within kidney cells, simu-
lations were conducted in which cidofovir was adminis-
tered alone or in combination with probenecid (using a Ki
of 1 lM; see Sect. 3). The effects of differential and
simultaneous inhibition of Tup,b and Teff,a by probenecid on
intracellular exposure to cidofovir were explored.
2.6 PBPK Simulation Design
The dosage designs all mimicked those described in the
referenced observed studies. Unless specified otherwise, all
simulations were deterministic in order to illustrate the
effects of patient factors. Deterministic simulations were
accomplished using the ‘Population Representative’ feature
of the software.
2.7 Approximation of the Standard Deviation
of the Observed Mean AUC Ratio
In the referenced renal impairment and DDI studies, the
observed results were reported as mean area under the
concentration–time curve (AUC) values with
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corresponding variance for each study condition (control
versus renal impairment population or DDI arm). The
AUCR values were calculated and standard deviations
were approximated using corresponding variance expres-
sion for the ratio of two independent variables based on the
bivariate first-order Taylor expansion [15].
3 Results
3.1 Can PBPK Modelling Describe Kidney Drug
Transport for Compounds that Undergo Active
Renal Secretion?
Three model drugs—oseltamivir carboxylate, cidofovir and
cefuroxime—were chosen on the basis of the criteria that
they are all predominantly renally cleared, with sufficient
plasma/serum and urinary drug concentration–time pro-
files, and that systemic exposure to each of these drugs has
been shown to be altered in subjects with renal impairment
and when co-administered with probenecid. Using a PBPK
framework integrated with a mechanistic kidney structure
[1] (Fig. 1), we developed models for each of the model
drugs and estimated the contribution of both Tup,b and Teff,a
transporter(s) to active secretion. Plasma pharmacokinetic
data were used to determine CLint,T for Tup,b. Although
CLint,T for Teff,a remains unidentifiable even after CLint,T
for Tup,b is defined (Fig. 1), urine excretion profiles (e.g.
the amount excreted over time) were used to suggest a
plausible value of CLint,T for Teff,a for each drug. These
PBPK models included detailed physiological determinants
describing the dynamics of drug disposition, and could be
used to predict and evaluate the impact of renal impairment
or co-administration of the transporter inhibitor probenecid
(an intrinsic patient factor and an extrinsic factor, respec-
tively) on systemic drug levels and urinary excretion pro-
files (see the Electronic Supplementary Material).
3.2 Can Changes in Transporter Activity by Severe
Renal Impairment be Derived Using PBPK
Modelling?
Initially, when the PBPK drug models only considered
GFR changes in subjects with severe renal impairment
(CLCR \30 mL/min, software ‘RenalGFR_less_30’ popu-
lation), the plasma AUCRRI/Normal values were only pre-
dicted to be 3 to 5.5-fold, considerably lower than mean
AUCR values of 7.5, 9.8 and 13-fold observed for ci-
dofovir, cefuroxime and oseltamivir carboxylate, respec-
tively. In order to reflect the effect of severe renal
impairment on active transport processes, a sensitivity
analysis of PTCPGK, a system-dependent parameter, was
performed in subjects with severe renal impairment. The
predicted AUCRRI/Normal values for each compound were
plotted against PTCPGK values ranging from 0.1 9 106 to
the default 60 million PTCPGK [1] and compared with the
observed AUCR values (Fig. 2).
Both oseltamivir carboxylate and cefuroxime required
more than a ten-fold downgrade from the baseline
PTCPGK value in subjects with severe renal impairment to
predict their respective observed AUCR values. A fifteen-
fold reduction in PTCPGK (to 4 million PTCPGK; Fig. 2a)
Fig. 2 Evaluation of the effects of theoretical changes in the number
of proximal tubular cells per gram kidney (PTCPGK) on plasma
exposure changes (AUCR, severe renal impairment versus normal
renal function) in severe renal impairment. The dashed lines represent
the simulated AUCR, and the solid lines ± shade represent observed
the mean ± SD AUCR. The tested PTCPGK values ranged from 0.1
to 60 million proximal tubular cells per gram of kidney. a Oseltamivir
carboxylate: 100 mg oral multiple dose (single dose on day 1, twice
daily on days 2–5, single dose on day 6) in subjects with severe renal
impairment and healthy subjects [7]. b Cidofovir: 0.5 mg/kg intra-
venous infusion over 1 h in subjects with severe renal impairment and
healthy subjects [9, 30] (note: in both simulated and observed studies,
cidofovir was co-administered with oral probenecid to reduce
nephrotoxicity). c Cefuroxime: 750 mg intravenous bolus dose over
2 min in subjects with severe renal impairment and healthy subjects
[8]
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in the severe renal impairment population in the oseltam-
ivir carboxylate PBPK model resulted in a simulated AUC
that was 10.0-fold higher than that in healthy subjects,
similar to an observed mean AUC increase of 10.3-fold.
Likewise, for cefuroxime, a 15-fold reduction in PTCPGK
resulted in a simulated AUC that was 9.1-fold higher than
that in healthy subjects, comparable to a mean AUC
increase of 9.8-fold observed in severe renal impairment
(Fig. 2c).
For cidofovir, both healthy subjects and those with
severe renal impairment were concomitantly dosed with
oral probenecid to reduce the drug’s nephrotoxicity. In
these studies, the active secretion process would have been
largely inhibited by probenecid (see Sect. 3.3 below),
resulting in an apparent lack of response to decreasing
PTCPGK values in subjects with severe renal impairment
(Fig. 2b). The model predicted a 5.5-fold increase in the
AUC in subjects with severe renal impairment, regardless
of the PTCPGK value defined in this population. The
observed mean AUC increase was 7.5-fold.
3.3 Can the In Vivo Inhibition Potency of Probenecid
on Renal Transporters Be Derived Using PBPK
Modelling?
In vitro information is limited for probenecid with regard
to its inhibition potency and specificity towards renal
transporters. We conducted PBPK modelling to derive the
apparent in vivo Ki of probenecid by assuming reversible
inhibition on Tup,b of the substrate drugs. A sensitivity
analysis was conducted over a range of Ki values in the
probenecid PBPK model, targeting Tup,b. A Ki value in the
range of 0.1 to 10 lM appeared to predict the observed
mean AUCR for oseltamivir carboxylate. For example, at
Ki = 1 lM, the PBPK predicted exposure change for
oseltamivir carboxylate was 2.2-fold when oseltamivir
phosphate was co-administered with probenecid, and the
observed mean AUCR for oseltamivir carboxylate was 2.5-
fold (Fig. 3a). For cidofovir, the predicted AUCR was not
sensitive to the in vivo Ki value. At a[1,000-fold range of
Ki values (0.1–100 lM), the predicted exposure changes
for cidofovir were between 1.1 and 1.4, and the observed
mean AUCR was 1.3 (Fig. 3b). For cefuroxime, a Ki value
around 10 lM predicted the observed mean AUCR values
(1.6 and 1.4 for the predicted and observed AUCR values,
respectively; Fig. 3c). As the Ki value decreased, the model
appeared to overpredict the AUC increase for cefuroxime.
3.4 Can PBPK Modelling Be Used to Evaluate
the Role of Renal Transporters on Drug Exposure
in Kidney Cells, With or Without Co-
administration of a Transporter Inhibitor?
Since cidofovir accumulation in kidney cells is believed to
correlate with its nephrotoxicity under clinical dosing [13,
14], we investigated the hypothetical effect of differential
and simultaneous inhibition of the net basolateral uptake
and apical efflux transporters (Fig. 1) by probenecid, using
PBPK. Maximal cidofovir exposure in kidney cells after an
intravenous drug infusion was simulated in different inhi-
bition scenarios (Table 2). A Ki value of 1 lM in the
probenecid PBPK model was chosen for Tup,b on the basis
of the analyses in Sect. 3.3. When the model assumed
inhibition on Tup,b only, the simulated amount of cidofovir
in kidney cells decreased substantially, compared with ci-
dofovir administration alone. In contrast, kidney cells were
exposed to significantly greater amount of cidofovir when
the model assumed inhibition of Teff,a only. When
Fig. 3 Evaluation of the effects of use of different probenecid
inhibition constant (Ki) values on simulated plasma exposure changes
of test substrates (AUCR, with and without inhibitor). The dashed
lines represent the simulated AUCR, and the solid lines ± shade
represent the observed mean ± SD AUCR. a Oseltamivir
carboxylate: 150 mg single oral dose with and without probenecid
[12]. b Cidofovir: 3.0 mg/kg intravenous infusion over 1 h with and
without probenecid [9]. c Cefuroxime: 750 mg intravenous infusion
over 20 min with and without probenecid [31]
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simultaneous inhibition of Tup,b and Teff,a was assumed to
be inhibited by probenecid, using Ki = 1 lM for both, the
predicted kidney exposure was about 40 % lower than the
condition without inhibition. The simulated 24 h time
profile of the drug amount in kidney cells from these
simulations can be found in Fig. S6 in the Electronic
Supplementary Material.
4 Discussion
This study provides a framework for modelling active drug
secretion in the kidneys, using PBPK. With consideration
of detailed drug disposition mechanisms in the kidney, we
addressed each of the questions posed in Sect. 3.
4.1 Can PBPK Modelling Describe Kidney Drug
Transport for Compounds that Undergo Active
Renal Secretion?
In order to successfully predict the effects of patient factors
on drug pharmacokinetics, the quantitative contribution of
each disposition pathway and the effects of patient factors
on the pathway need to be defined a priori. Specifically for
drug transporters, there is often a lack of information
regarding transporter specificity between a substrate (which
is often mediated by multiple transporters) and a perpetrator
drug (which often inhibits multiple transporters). Present
knowledge gaps in system-dependent parameters (e.g. the
effect of renal impairment on drug transporters and absolute
transporter abundance) further hinder the prediction.
However, using a PBPK model with sufficient mechanistic
complexity, supported by suitable sets of in vivo data, one
can discern the impact of patient factors on a specific
pathway to identify or even fill the knowledge gaps.
4.2 Can Changes in Transporter Activity by Severe
Renal Impairment Be Derived Using PBPK
Modelling?
We and others have used PBPK modelling to hypothesize that
severe kidney dysfunction significantly affects hepatic uptake
transporters [6, 16]. In this study, we extended the use of
PBPK modelling to quantify the effect of renal impairment on
renal transporter activities, using model compounds. Initially,
the use of a predefined severe renal impairment population,
assuming unchanged intrinsic renal secretion, underestimated
the exposure changes in our test compounds. The predicted
AUC increase in this population versus the population with
normal renal function was at most 3-fold for drugs such as
oseltamivir carboxylate and cefuroxime, whereas 9.8- to
10-fold increases had been observed, suggesting a potential
effect of decreased renal function also on the non-filtration
pathway (Fig. 2). Decreased renal function is known to cor-
relate with pathological changes in the glomerulus and tubular
interstitium of the kidney [17, 18], and conditions such as
albuminuria have been hypothesized to induce scar damage
[19–22]. As such, a common end result of chronic kidney
disease is renal fibrosis, characterized by significant tissue
scarring, leading to total damage of kidney parenchyma [23]
and thereby affecting both filtration and secretion elimination
pathways. Additionally, kidney disease, such as bilateral
ureteral obstruction, is known to correlate with downregula-
tion of the uptake transporters OAT1 and OAT3 in proximal
tubule cells in rats [24]. According to Eq. 1, PTCPGK is a key
system-scaling factor for determining the contribution of a
transporter to renal clearance. We conducted sensitivity
analyses by predicting the AUCRRI/Normal over a range of
PTCPGK values under the assumption that the other two
parameters remain unchanged in subjects with renal impair-
ment. The results of our simulations showed that a decrease of
at least ten-fold in the PTCPGK value from the baseline (i.e.
from 60 million to B 6 million) was necessary to predict the
observed AUC changes in subjects with severe renal impair-
ment. It is important to emphasize that we are not proposing
the PTCPGK drop as an unequivocal mechanistic explanation
for renal impairment, but as a practical singular means of
simulating renal impairment affecting the secretion pathway,
using PBPK.
The effect on alteration of PTCPGK in renal impairment
cannot be derived for cidofovir, because of the presence of
probenecid in its renal impairment study to reduce nephro-
toxicity, which in theory would have abolished the secretion
pathway (Fig. 2b showed the insensitivity of the plasma
exposure in renal impairment with the changes in PTCPGK).
However, the cidofovir simulations represented a good
example of using PBPK modelling to simulate the dynamic
effects of both renal impairment and DDI on multiple dis-
position processes of a drug.
Table 2 Maximum simulated amount of cidofovir in kidney cells
(24 h post-dosing) following a 3.0 mg/kg cidofovir intravenous
infusion over 1 h with and without probenecid inhibition




With probenecid (using Ki = 1 lM)
Net basolateral uptake onlya 0.001
Net apical efflux onlya 0.656
Uptake and efflux 0.014
Ki reversible inhibition constant
a Net basolateral uptake (Tup,b) and apical efflux (Teff,a) transport
processes designated in the physiologically based pharmacokinetic
models (Fig. 1)
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This [10-fold reduction in PTCPGK allows us to pre-
dict the effect of severe renal impairment on the active
transport component of renal clearance for an investiga-
tional drug, using the PBPK approach. Studies are under-
way to confirm the extrapolation capability of this finding,
using other renally eliminated drugs.
4.3 Can the In Vivo Inhibition Potency of Probenecid
on Renal Secretion Be Derived Using PBPK
Modelling?
Both oseltamivir carboxylate and cidofovir are substrates
of OAT1 in vitro [10, 12]. The reported in vitro probenecid
Ki values against OAT1 were 1–30 lM [10–12, 25, 26]. In
this study, inhibition of Teff,a was not considered, as it
would not affect plasma pharmacokinetics when the pas-
sive process was assumed to be negligible (see Sect. 2).
In vivo probenecid Ki values towards Tup,b appear to be
B1 lM for oseltamivir carboxylate and *10 lM for ce-
furoxime in order to predict the observed AUCR. Cidofovir
is not sensitive to a range of Ki values tested, likely because
of a much smaller contribution of secretion clearance to its
total renal clearance (\40 %; Table 1).
Increased cefuroxime systemic exposure in the presence
of probenecid could be predicted by PBPK simulations
only when Ki is between 10 and 100 lM. Use of proben-
ecid Ki B1 lM (as for oseltamivir carboxylate simulations)
overpredicted the AUCR value for cefuroxime. One plau-
sible explanation may be that specific inhibition of differ-
ent uptake transporters for each test substrate was not
captured in the model (the contribution of a specific
transporter to total Tup,b for cefuroxime that could be
inhibited by probenecid was unknown).
Currently, if an investigational drug (in particular, an
organic anion) is found to be significantly secreted in the
kidney, a clinical study using probenecid may be recom-
mended to determine the effect of co-adminnistration with
probenecid and/or other inhibitors of renal basolateral
organic anion transporters. In the absence of transporter
specificity information, our simulations suggest a practical
use of PBPK to assess the risk of interaction with probenecid.
The developed probenecid PBPK model with an unbound Ki
value of B1 lM on net Tup,b would provide an initial estimate
of AUCR values in the presence of probenecid.
4.4 Can PBPK Modelling Be Used to Evaluate
the Role of Renal Transporters on Drug Exposure
in Kidney Cells, With or Without Co-
administration of a Transporter Inhibitor?
Using PBPK models, the effect of transporter inhibition by
probenecid on cidofovir kidney cell exposure was simu-
lated (Table 2). Simulations showed that probenecid likely
inhibits kidney uptake transporter(s) and decreases expo-
sure to cidofovir in kidney cells. Inhibition of only apical
efflux of cidofovir would cause significant accumulation of
the drug in kidney cells, which would greatly exacerbate
cidofovir’s known nephrotoxic effects.
4.5 Limitations of the Current Study
Though the current study demonstrated important uses of
PBPK modelling in predicting the effects of patient
factors on systemic and renal drug levels and on DDIs,
some limitations should be noted. First, the three drugs
used in the study are all organic anions. Therefore, it is
not known whether the conclusion based on the devel-
oped PBPK model would apply to organic cations, which
are eliminated by a different set of renal transporters
with distinct mechanisms. Second, the drugs used in the
study were eliminated in large part by secretion in the
kidney. Further research is needed to evaluate the utility
of this PBPK approach for drugs with smaller compo-
nents of secretion, whose renal elimination is sensitive to
urine pH and flow, and which undergo reabsorption, or
drugs which undergo significant elimination by renal and
hepatic pathways.
5 Conclusion
This study demonstrated the practical use of PBPK
modelling, with a clearly defined mechanistic kidney
model, to evaluate the effects of patient factors on kid-
ney uptake and efflux transporters, using three predom-
inantly renally cleared model drugs. The results showed
that for an investigational drug whose filtration and
active secretion pathways are quantitatively known, one
can use PBPK approaches to (1) practically define
transporter-mediated renal secretion, using plasma and
urine data; (2) predict the effect of severe renal
impairment on the exposure change of the drug,
assuming a 10-fold reduction in functional tubule cells in
conjunction with a reduced filtration rate in the model;
(3) predict the effect of inhibition of kidney uptake
transport by probenecid, using a conservative in vivo Ki
(B1 lM); and (4) evaluate the effect of transporter
inhibition on drug exposure in kidney cells. These find-
ings could be confirmed with future PBPK modelling of
other drugs that undergo renal elimination.
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